Arrowhead Pharma reports FY22 revenue up but net loss widens to $172.7M; $250M royalty sale

ARROWHEAD PHARMACEUTICALS, INC.

2022-FY EPS reported -$1.67 revenue$243,231,000

Revenue $243.2M for FY22 (Sep 30 yr-end), up 76% from $138.3M in FY21.
Net loss $172.7M ($1.67 diluted loss per share) vs $140.8M ($1.36) prior year.
Sold olpasiran royalty interest to Royalty Pharma for $250M cash plus up to $160M milestones.
Phase 2 studies for ARO-APOC3 and ARO-ANG3 fully enrolled; new Phase 1/2a starts for ARO-MUC5AC, ARO-RAGE, ARO-MMP7.
Cash and investments $482.3M at Sep 30, 2022, down from $613.4M at Sep 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.